Tumor Biology

, Volume 36, Issue 5, pp 3637–3642 | Cite as

Activation of FGF receptor signaling promotes invasion of non-small-cell lung cancer

  • Deping Zhao
  • Yi Lu
  • Chenlu Yang
  • Xiao Zhou
  • Zhifei Xu
Research Article


The molecular regulation of metastasis of non-small-cell lung cancer (NSCLC) remains not completely defined. Here we showed significant higher MMP26 in the resected NSCLC than adjacent healthy tissue from the patients. Moreover, a strong correlation between MMP26 and the phosphorylated fibroblast growth factor receptor 1 (FGFR1) was detected. To examine the causal relationship between activated FGFR signaling and MMP26, we studied a human NSCLC cell line, A549. We found that FGF1-induced FGFR1 phosphorylation in A549 cells activated MMP26, resulting in an increase in cancer invasiveness. Inhibition of FGFR1 phosphorylation abolished FGF1-stimulated MMP26 activation, suggesting that activation of FGFR signaling pathway in NSCLC promotes cancer metastasis through MMP26. To define the signal transduction cascades downstream of FGFR1 activation for MMP26 activation, we used specific inhibitors for PI3K, ERK/MAPK, and JNK, respectively, to the FGF1-stimulated A549 cells. We found that only inhibition of JNK significantly decreased the activation of MMP26 in response to FGF1 stimulation, suggesting that activation of FGFR1 signaling may activate JNK to activate MMP26 in NSCLC. Our study thus highlights FGFR signaling pathway and MMP26 as novel therapeutic targets for NSCLC therapy.


Fibroblast growth factor receptor 1 Non-small-cell lung cancer (NSCLC) MMP26 A549 ERK/MAPK PI3K JNK 



This work was financially supported by National Nature Science Foundation of China (81001036) and Shanghai Municipal Commission of Health and Family Planning (2010Y066).

Conflicts of interest



  1. 1.
    Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (nsclc). J Thorac Dis. 2013;5:S389–96.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Mitsudomi T, Suda K, Yatabe Y. Surgery for nsclc in the era of personalized medicine. Nat Rev Clin Oncol. 2013;10:235–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of nsclc. Lung Cancer. 2013;80:120–30.CrossRefPubMedGoogle Scholar
  4. 4.
    Jian H, Zhao Y, Liu B, Lu S. Sema4b inhibits mmp9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014;35:11051–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Pei J, Lou Y, Zhong R, Han B. Mmp9 activation triggered by epidermal growth factor induced foxo1 nuclear exclusion in non-small cell lung cancer. Tumour Biol. 2014;35:6673–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Takaishi H, Kimura T, Dalal S, Okada Y, D’Armiento J. Joint diseases and matrix metalloproteinases: a role for mmp-13. Curr Pharm Biotechnol. 2008;9:47–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (mmp-1, mmp-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res. 2002;4:157–64.CrossRefPubMedGoogle Scholar
  8. 8.
    Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C. Expression and regulation of collagenase-3 (mmp-13) in human malignant tumors. APMIS. 1999;107:45–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Li D. Peaking of mmp-26 and timp-4 marks invasive transition in prostate cancer. Cell Res. 2006;16:741.CrossRefPubMedGoogle Scholar
  10. 10.
    Yamamoto H, Vinitketkumnuen A, Adachi Y, Taniguchi H, Hirata T, Miyamoto N, et al. Association of matrilysin-2 (mmp-26) expression with tumor progression and activation of mmp-9 in esophageal squamous cell carcinoma. Carcinogenesis. 2004;25:2353–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang Y, Zhao H, Wang Y, Lin Y, Tan Y, Fang X, et al. Non-small cell lung cancer invasion and metastasis promoted by mmp-26. Mol Med Rep. 2011;4:1201–9.PubMedGoogle Scholar
  12. 12.
    Li L, Mei TH, Zhou XD, Zhang XG. Expression and clinical significance of matrix metalloproteinase (mmp)-26 protein in non-small cell lung cancer. Ai Zheng. 2009;28:60–3.PubMedGoogle Scholar
  13. 13.
    Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemost. 1999;82:748–54.PubMedGoogle Scholar
  14. 14.
    Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta. 1992;1135:185–99.CrossRefPubMedGoogle Scholar
  15. 15.
    Fujimoto J, Hori M, Ichigo S, Tamaya T. Expressions of the fibroblast growth factor family (fgf-1, −2 and −4) mrna in endometrial cancers. Tumour Biol. 1996;17:226–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires mapk/erk signaling downstream of fibroblast growth factor receptor 1. J Neurosci. 2010;30:6595–606.CrossRefPubMedGoogle Scholar
  17. 17.
    Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through mek-erk is required for prostate bud induction. Differentiation. 2007;75:638–51.CrossRefPubMedGoogle Scholar
  18. 18.
    Williamson AJ, Dibling BC, Boyne JR, Selby P, Burchill SA. Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38mapk and up-regulation of the death receptor p75ntr. J Biol Chem. 2004;279:47912–28.CrossRefPubMedGoogle Scholar
  19. 19.
    Kan M, Wu X, Wang F, McKeehan WL. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem. 1999;274:15947–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations in the fgfr pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Parker BC, Engels M, Annala M, Zhang W. Emergence of fgfr family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol. 2014;232:4–15.CrossRefPubMedGoogle Scholar
  22. 22.
    Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable fgfr gene fusions in diverse cancers. Cancer Discov. 2013;3:636–47.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Beau-Faller M, Gaub MP, Schneider A, Guerin E, Meyer N, Ducrocq X, et al. Allelic imbalance at loci containing fgfr, fgf, c-met and hgf candidate genes in non-small cell lung cancer sub-types, implication for progression. Eur J Cancer. 2003;39:2538–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, et al. Novel fgfr inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing fgfr1. Oncol Rep. 2013;29:2181–90.PubMedGoogle Scholar
  25. 25.
    Volm M, Koomagi R, Mattern J, Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (fgfr-1) in patients with non-small cell lung carcinomas. Eur J Cancer. 1997;33:691–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type ii alveolar epithelial cells. Int J Cancer. 1976;17:62–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Kang M, Choi S, Jeong SJ, Lee SA, Kwak TK, Kim H, et al. Cross-talk between tgfbeta1 and egfr signalling pathways induces tm4sf5 expression and epithelial-mesenchymal transition. Biochem J. 2012;443:691–700.CrossRefPubMedGoogle Scholar
  28. 28.
    Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Xu Y, Xia W, Baker D, Zhou J, Cha HC, Voorhees JJ, et al. Receptor-type protein tyrosine phosphatase beta (rptp-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (hgfr/met) function. J Biol Chem. 2011;286:15980–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Thoracic Surgery, Changzheng HospitalSecond Military Medical UniversityShanghaiChina
  2. 2.Department of Thoracic SurgeryPudong District People’s HospitalShanghaiChina
  3. 3.Department of Thoracic SurgeryShanghai Pulmonary Hospital of Tongji UniversityShanghaiChina

Personalised recommendations